[Anabolic therapy in metastatic breast cancer].
The medical records of 66 women treated with metenolone for metastasized breast carcinomas were analysed. In 26 patients a remission developed with a mean duration of 8.2 (3-29) months. Patients whose treatment started in the first year after the menopause as well as patients with a beneficial effect of a therapeutic ovariectomy in the past were more often improved by metenolone than average. Metenolone had a better effect against osseous metastases than against visceral metastases. In most cases the treatment was well tolerated. In four patients, however, the treatment had to be interrupted because of cholestasis, pulmonary embolism and hypercalcaemia.
D000328:Adult; D000368:Aged; D045930:Anabolic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000556:secondary; D002369:Castration; D005260:Female; D006801:Humans; D008408:Mastectomy; D008593:Menopause / Q000187:drug effects; D008710:Methenolone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged
D045930:Anabolic Agents; C028758:methenolone enanthate; D008710:Methenolone; C033244:methenolone acetate
Anabole Therapie bei metastasierendem Mamma-Karzinom.